BILL ANALYSIS

HR6130

BULLISH

ASAP Act

HR6130 (ASAP Act) has been assessed with a bullish outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

bullish

Market Sentiment

5/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

ASAP Act mandates Medicare coverage for blood-based dementia tests — no cash-pay barrier for seniors starting 2028.

Primary beneficiaries: Labcorp ($LH) and Quest ($DGX), the two independent labs with existing FDA-cleared blood-based dementia tests.

Bill is early stage but has 82 cosponsors + Senate companion — strong bipartisan momentum for mid-2027 passage.

QuidelOrtho ($QDEL) and Revvity ($RVTY) have diagnostics exposure but lack direct FDA-cleared dementia blood tests — secondary beneficiaries at best.

How HR6130 Affects the Market

Both $LH and $DGX have declined over the past 30 days (LH: -3.62% to $257.16; DGX: -2.55% to $191). This is NOT driven by dementia policy news; it reflects general market weakness in the healthcare services sector. The ASAP Act is a positive fundamental catalyst that is not yet priced into these stocks. As the bill progresses through committee and toward passage, the market should begin to price in the incremental revenue from mandatory Medicare coverage. Investors should view current price levels as attractive entry points given the de-risked regulatory pathway (FDA-cleared tests already exist) and the certainty of the January 1, 2028 effective date if passed.

Bill Details

Metric	Value
Bill Number	HR6130
Market Sentiment	bullish
Event Date	November 19, 2025
Affected Sectors	Healthcare
Source	View on Congress.gov →

Summary

The ASAP Act (HR6130) mandates Medicare coverage for FDA-cleared blood-based dementia screening tests starting Jan 1, 2028. Labcorp ($LH) and Quest Diagnostics ($DGX) are the two largest independent lab operators with existing FDA-cleared blood-based dementia tests, making them primary beneficiaries of this new mandatory benefit category. The bill is in early legislative stages (referred to committee) with companion bill S3267 in the Senate, but the bipartisan sponsorship and 82 cosponsors indicate strong momentum for a mid-2027 passage timeline.

Full AI Market Analysis

The ASAP Act (HR6130), introduced November 19, 2025 by Rep. Buchanan (R-FL) with 82 cosponsors, amends the Social Security Act to mandate Medicare coverage for blood-based Alzheimer's disease and related dementias screening tests beginning January 1, 2028. The bill explicitly defines these tests as FDA-cleared or approved genomic sequencing blood tests or equivalent blood-based tests. This is not an authorization bill with a spending ceiling — it mandates coverage under existing Medicare Part B, meaning CMS must establish a reimbursement rate (likely under the Clinical Laboratory Fee Schedule) once the bill becomes law. The money trail is structural: Medicare covers approximately 60 million Americans aged 65+. Blood-based dementia screening is currently a cash-pay or limited private-pay market. Mandatory Medicare coverage would make these tests available without patient out-of-pocket costs (after deductible), dramatically expanding the addressable patient population. The bill does not authorize a specific dollar amount; instead, it creates a new mandatory spending category within Medicare Part B. Estimated annual Medicare spending could range from $1B to $3B depending on utilization rates and the final CMS payment rate. Structural winners are Labcorp ($LH) and Quest Diagnostics ($DGX). Both have existing FDA-cleared blood-based dementia tests on the market. Labcorp's test (amyloid tau panel with NFL) and Quest's AD-Detect both target the exact population and test type described in the bill. Smaller diagnostics players ($QDEL, $RVTY) are also in the blood diagnostics space — QuidelOrtho has a cardiac/neurology assay portfolio, and Revvity operates in the applied genomics space — but neither has a directly comparable FDA-cleared blood-based dementia screening test, making their benefit less direct. Their recent 30-day price declines (-29.7% for QDEL, -5.27% for RVTY) reflect broader sector weakness, not dementia-specific headwinds. The legislative timeline: the bill is in early stages, referred to Energy & Commerce and Ways & Means in the House. Companion bill S3267 was introduced in the Senate. With 82 cosponsors and bipartisan sponsorship, the bill has strong early support, but must pass both chambers and be signed into law before the January 1, 2028 effective date. The most likely passage window is late 2026 or mid-2027. Investors should monitor committee hearings and markups as key catalysts.